Endostatin
Endostatin is a naturally-occurring, 20-kDa C terminal fragment derived from type XVIII collagen. It is reported to serve as an antiangiogenic agent, similar to angiostatin and thrombospondin.
Endostatin is a broad-spectrum antiangiogenic and may interfere with the pro-angiogenic action of growth factors such as basic fibroblast growth factor (bFGF/FGF-2) and vascular endothelial growth factor (VEGF).
Gene therapy with endostatin delivered via Semliki Forest virus may be a candidate for the development of a new treatment for brain tumors 1).
A study demonstrates the potential efficacy of intramuscular delivery of antiangiogenic gene for treatment of metastatic brain tumor 2).
Results indicate a positive correlation between the levels of tissue endostatin and malignancy grades in gliomas. The endostatin may be released near the tumor blood vessels with hyperplasia to counteract angiogenic stimuli in malignant gliomas 3)
The cloning, expression and preliminary application of human endostatin protein lay the foundation for the antiangiogenesis therapy of glioma and the other solid tumors 4)
Encapsulated endostatin-secreting cells are effective for the treatment of human glioblastoma xenografts. Continuous local delivery of endostatin may offer an effective therapeutic approach to the treatment of a variety of tumor types 5).